Nurix Therapeutics, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 5 Aug 2026Quarterly earnings show how the company is performing financially and spending money on drug development.
Quarterly earnings reports help investors understand if the company is making progress toward profitability.
Clinical trial updates show whether the company's drug development is working and could lead to future sales.
This major partnership brings immediate cash and potential $2.3 billion total, significantly funding the company's future.
Board elections and auditor approval show how shareholders are overseeing company leadership and finances.
Quarterly earnings help investors track company spending and progress on developing drug treatments.
Quarterly earnings show company performance and help investors see if cash is lasting through development stage.
Stocky reads Nurix Therapeutics, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Nurix Therapeutics, Inc.'s most recent tracked filing was a 10-Q on 9 Jul 2026: Nurix reports Q2 2026 financial results for quarter ended May 31.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 5 Aug 2026.